|
|
|
|
|
Cilostazol
drug data and news
Cilostazol drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Cilostazol | ||
| Brand Names/Synonyms | CHEMBANK2857; Cilostazol; Cilostazol [Inn:Jan]; Cilostazole; Cilostazolum [Inn-Latin]; OPC 21; Pletaal; Pletal | ||
| Indication | For the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Cilostazol is a quinolinone derivative indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance. Intermittent claudication is pain in the legs that occurs with walking and disappears with rest. The pain occurs due to reduced blood flow to the legs. | ||
| Mechanism Of Action | The mechanism of the effects of Cilostazol on the symptoms of intermittent claudication is not fully understood. Cilostazol and several of its metabolites are cyclic AMP (cAMP) phosphodiesterase III inhibitors (PDE III inhibitors), inhibiting phosphodiesterase activity and suppressing cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation. | ||
| Cilostazol News (When available) |
Acetaminophen May Help Pain but Not Heart after Heart Attack 16 May 2006 Mylan Labs Gets FDA Approval For Cilostazol Tablets; Shipments ... Apr 25, 2006 FDA Approves Generic Cholesterol and Leg Pain Drugs Apr 25, 2006 Mylan Laboratories Q4 Profit Rises 51%, Tops Estimates; Reaffirms ... May 9, 2006 Business news briefs: 4/26/06 Apr 25, 2006 | ||
| Dosage Forms | Not Available | ||
| Drug_Category | Neuroprotective Agents; Vasodilator Agents; Fibrinolytic Agents; Bronchodilator Agents; ATC:C04AD | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Cilostazol: Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole. Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A.. Pletal does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on lovastatin, a drug with metabolism very sensitive to C.P.A. inhibition. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one | ||
| Chemical Formula | C20H27N5O2 | ||
| Molecular Weight | 369.461 g/mol | ||
| Smiles String | C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4 | ||
| Melting Point | 160 °C | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 2.686 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 11-13 hours. | ||
| Protein Binding [%] | 95-98% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Cilostazol.html http://www.rxlist.com/cgi/generic/cilostaz.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00155 | ||
| CAS Registry Number | 73963-72-1 | ||
| KEGG Compound ID | C13368 | ||
| PubChem ID | SID:190773 | ||
| PharmGKB ID | PA449000 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |